419 related articles for article (PubMed ID: 14506195)
21. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
22. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
Rupp U; Schoendorf-Holland E; Eichbaum M; Schuetz F; Lauschner I; Schmidt P; Staab A; Hanft G; Huober J; Sinn HP; Sohn C; Schneeweiss A
Anticancer Drugs; 2007 Apr; 18(4):477-85. PubMed ID: 17351401
[TBL] [Abstract][Full Text] [Related]
23. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
24. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
Wong JY; Williams LE; Yamauchi DM; Odom-Maryon T; Esteban JM; Neumaier M; Wu AM; Johnson DK; Primus FJ; Shively JE
Cancer Res; 1995 Dec; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
Breitz HB; Weiden PL; Vanderheyden JL; Appelbaum JW; Bjorn MJ; Fer MF; Wolf SB; Ratliff BA; Seiler CA; Foisie DC
J Nucl Med; 1992 Jun; 33(6):1099-109. PubMed ID: 1597723
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
27. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
28. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
[TBL] [Abstract][Full Text] [Related]
29. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R
Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
[TBL] [Abstract][Full Text] [Related]
31. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
32. Maximum tolerated dose and large tumor radioimmunotherapy studies of 64Cu-labeled monoclonal antibody 1A3 in a colon cancer model.
Connett JM; Buettner TL; Anderson CJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3207s-3212s. PubMed ID: 10541365
[TBL] [Abstract][Full Text] [Related]
33. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
34. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
[TBL] [Abstract][Full Text] [Related]
35. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma.
Riechelmann H; Sauter A; Golze W; Hanft G; Schroen C; Hoermann K; Erhardt T; Gronau S
Oral Oncol; 2008 Sep; 44(9):823-9. PubMed ID: 18203652
[TBL] [Abstract][Full Text] [Related]
37. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.
Riva P; Franceschi G; Frattarelli M; Lazzari S; Riva N; Giuliani G; Casi M; Sarti G; Guiducci G; Giorgetti G; Gentile R; Santimaria M; Jermann E; Maeke HR
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3275s-3280s. PubMed ID: 10541375
[TBL] [Abstract][Full Text] [Related]
38. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
Kotzerke J; Glatting G; Seitz U; Rentschler M; Neumaier B; Bunjes D; Duncker C; Dohr D; Bergmann L; Reske SN
J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience.
Colnot DR; Quak JJ; Roos JC; de Bree R; Wilhelm AJ; Snow GB; van Dongen GA
Head Neck; 2001 Jul; 23(7):559-65. PubMed ID: 11400244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
